

13 January 2026

Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and blood products

I would like to submit an FOI request for the number of **vials used** and **patients treated** for the following products (see table below) at your trust used in 2025 (total January to December), broken down **by brand and size**, if possible. If the full-year data is not yet available, you can inform me about the currently available data.

If not all products are available at your institution, you can just fill in the data that you have access to.

Product	Manufacturer	Size (Units/mg)	Number of vials used (Jan 19-Dec 2025)	Number of patients treated (Jan 19-Dec 2025)
Prothrombin Complex Concentrate (PCC)				
Beriplex	CSL Behring	500IU 20ml		
		1000IU 40ml		
Octaplex	Octapharma	500IU 20ml		
		1000IU 40ml		
Prothromplex	Takeda	600IU 17ml		
FEIBA	Takeda	200IU 10ml		
		500IU 20ml		
		1000IU 40ml		
Others (if any please specify)		(if any please specify)		
Reversal Agents				
Ondexxya (andexanet alfa)	Astrazeneca	5x 200 mg		
Praxbind (Idaracizumab)	Boehringer Ingelheim	2x 2.5 g		
Fibrinogen Concentrate (FC)				



13 January 2026

RiaSTAP	CSL Behring	1.0g		
FibCLOT	LFB	1.5g		
Fibryga	Octapharma	1.0g		
Others (if any please specify)		(if any please specify)		
Fresh Frozen Plasma (FFP)				
Fresh Frozen Plasma	Blood banks			
Octaplas	Octapharma			
Cryoprecipitate				
Cryoprecipitate	Blood banks			
Labile Blood Products				
Whole blood	Blood banks			
Red blood cells	Blood banks			
Platelets	Blood banks			
Factor XIII				
Fibrogammin	CSL Behring	250IU 4ml		
		1250IU 20ml		

Please see the attached document with our information.